#USA #San Antonio #Breast Cancer #PreciseBreast #PreciseDx

PreciseDx Showcases Innovative Research at SABCS 2025

In a significant development for breast cancer diagnostics, PreciseDx, recognized for its groundbreaking AI tool, PreciseBreast, is set to present essential research at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS). Scheduled from December 9 to 12 in San Antonio, Texas, this event will feature three pivotal abstracts that not only reaffirm the efficacy of PreciseBreast in evaluating recurrence risks but also its potential in guiding treatment decisions for early-stage breast cancer.

Understanding PreciseBreast

PreciseBreast leverages advanced artificial intelligence to synthesize image data and clinical factors, ultimately generating a personalized PreciseBreast Score. This score enables healthcare providers to stratify patients based on their individual recurrence risks, offering a more tailored approach to breast cancer treatment. The integration of AI into pathology opens new avenues for improving patient outcomes, particularly in early-stage invasive breast cancer cases.

Research Highlights

The abstracts presented at the symposium will cover diverse aspects of the AI tool’s capabilities. The first, presented by Dr. Michael Donovan, focuses on the clinical validation of PreciseBreast using biopsy specimens. This research underscores the tool's ability to offer prognostic insights based on real-world clinical evidence.

The second presentation by Dr. Nicholas Stanzione delves into a compelling approach to phenotyping triple-negative breast cancer, highlighting how PreciseBreast can assess recurrence risk and treatment response in this challenging subtype of breast cancer.

Lastly, a collaborative effort from Lankenau Medical Center will present a prospective evaluation of the PreciseBreast AI tool, further expanding its applicability to early-stage invasive breast cancer risk stratification.

Advancing Understanding in Oncology

Eric Converse, CEO of PreciseDx, emphasizes the importance of these findings, stating, "These results build on our prior publications validating PreciseBreast's clinical and analytical accuracy in early-stage invasive breast cancer. By using the patient’s biopsy specimen, we can better stratify risk and enhance our understanding of treatments for patients with triple-negative breast cancer."

Moreover, Converse highlights the ongoing collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) to further validate the tool's predictive capabilities regarding chemotherapy benefits for patients with hormone receptor-positive, HER2-negative early breast cancer.

Future Impact

As the healthcare community anticipates these presentations, the potential of AI-driven tools like PreciseBreast stands to revolutionize the landscape of breast cancer diagnostics and treatment planning. The increasing emphasis on personalized medicine underscores the need for continuous innovation in biomedical technology, especially in oncology.

For further details on PreciseBreast and its impact, individuals can visit PreciseDx.ai.

With these exciting developments on the horizon at SABCS 2025, the commitment of PreciseDx to enhancing patient care through innovative technology will surely attract attention from healthcare professionals and researchers alike.